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Background
The regenerative capacity of mesenchymal stem cells
(MSCs) is contingent on their content of multipotent
progenitors [1]. Despite its importance to the efficacy of
MSC therapies, the clonal heterogeneity of MSCs
remains poorly defined. To address this deficiency, the
current study presents a novel high-capacity assay to
quantify the clonal heterogeneity in MSC potency and
demonstrates its utility to resolve regenerative properties
as a function of potency. Human bone marrow was the
source of MSCs in this study. The versatility and acces-
sibility of marrow-derived MSCs make them a standard
for many therapeutic applications.
Materials and methods
Primary MSCs were harvested from the iliac crest bone
marrow of healthy adult volunteers and cultured as pre-
viously described [2]. The in vitro assay developed for
this study utilizes a 96-well format to (1) clone fluores-
cent MSCs stained with CellTracker Green by limiting
dilution, (2) generate matched clonal colonies, (3) differ-
entiate 3 matched colonies per clone to quantify triline-
age potential to exhibit adipo-, chondro- and
osteogenesis as a measure of potency, and (4) cryopre-
serve the 4th matched colony of each clone in situ in an
undifferentiated state for future use. Clones of known
potency were evaluated for their colony-forming effi-
ciency as a measure of proliferation potential [3].
Expression of the heterotypic cell adhesion molecule
CD146 on the surface of MSC clones was measured
with flow cytometry.
Results
All eight categories of trilineage potential were detected
in human marrow MSCs. Multipotent MSCs had a
higher proliferation potential than lineage-committed
MSCs. Tripotent clones formed colonies with a median
efficiency of 50%, as compared with 14% and 1% for bi-
and unipotent clones, respectively (p < 0.01). Likewise,
colonies that formed from tripotent clones had the lar-
gest median diameter. CD146 may be a biomarker of
MSC potency. Histograms of fluorescence intensity from
pooled tripotent clones labeled with anti-CD146 anti-
body shifted to higher CD146 expression relative to the
parent MSC preparation from which the clones were
generated; whereas, the histograms for parent MSCs and
their unipotent progeny were similar. In particular, the
mean fluorescence intensity of tripotent clones was
nearly twice the value for the parent and unipotent
MSCs (p < 0.05).
Conclusions
The research presented here addresses a basic deficiency
in stem cell technology by developing a quantitative and
high-capacity assay to characterize the clonal heteroge-
neity of MSC potency. The data suggest a complex hier-
archy of lineage commitment in which proliferation
potential and CD146 expression diminish with loss of
potency. The capacity of multipotent MSCs for ex vivo
expansion and their differential expression of a potential
potency marker will facilitate rapid production of effica-
cious MSC therapies with consistent progenitor content.
The assay has numerous basic research and clinical
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applications given the importance of heterogeneity to
the therapeutic potential of MSCs.
Acknowledgements
We thank Alan Tucker for his assistance with flow cytometry, Dina Gaupp for
preparing samples for histology, and Prof. Darwin Prockop for his helpful
conversations and suggestions about this project. This research was
sponsored by grants to Prof. O’Connor from the National Institutes of Health
(R03EB007281) and National Science Foundation (BES0514242).
Author details
1Department of Chemical and Biomolecular Engineering, Tulane University,
New Orleans, LA 70118, USA. 2Scripps Research Institute, Jupiter, FL, 33458,
USA.
Published: 22 November 2011
References
1. Barrilleaux BL, Phinney DG, Prockop DJ, O’Connor KC: Ex vivo engineering
of living tissue with adult stem cells. Tissue Eng 2006, 12:3007-3019.
2. Barrilleaux BL, Phinney DG, Fischer-Valuck BW, Russell KC, Wang G,
Prockop DJ, O’Connor KC: Small-molecule antagonist of macrophage
migration inhibitory factor enhances migratory response of
mesenchymal stem cells to bronchial epithelial cells. Tissue Eng Part A
2009, 15:2335-2346.
3. Russell KC, Lacey MR, Gilliam JK, Tucker HA, Phinney DG, O’Connor KC:
Clonal analysis of proliferation potential of human bone marrow
mesenchymal stem cells as a function of potency. Biotechnol Bioeng 2011,
108:2716-2726, doi:10.1002/bit.23193.
doi:10.1186/1753-6561-5-S8-O14
Cite this article as: O’Connor et al.: High-capacity assay to quantify the
clonal heterogeneity in potency of mesenchymal stem cells. BMC
Proceedings 2011 5(Suppl 8):O14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
O’Connor et al. BMC Proceedings 2011, 5(Suppl 8):O14
http://www.biomedcentral.com/1753-6561/5/S8/O14
Page 2 of 2
